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Summary.-This is a study of cell kinetics in nodular and florid (fungating) Kaposi's
sarcomas. One or more tumours from 9 patients were examined at the Uganda
Cancer Institute. The very variable clinical doubling time was assessed by direct
measurements of tumour diameters, and an average obtained. The mitotic count,
rate of entry of cells into mitosis and cell cycle time were measured in biopsy
material, and used to estimate the potential doubling time. From the difference
between the potential and the actual doubling times, the rate of cell loss and the
cell loss factor were calculated.
The average actual clinical doubling time was slightly, but not significantly,
higher for growing nodular tumours than for florid tumours. Some nodular
tumours regressed, and one was static. The clinical doubling times of the growing
tumours were similar to those reported In the literature for other human malig-
nancies. Kinetic studies of static and regressing human tumours have not been
reported previously.
The rate of cell production found in this tumour is lower than the values reported
in the literature for other malignancies. The calculated mitotic duration is long,
but similar to previously reported values. The cell loss factor is high: in the static
tumour it is 1-0, and in the regressing tumours greater than 1.0. In regressing
tumours, the rate of cell loss was30% higher than the rate of cell production. These
tumours did not differ histologically from nearly florid tumours which were in-
creasing in size. It is postulated that regression is determined by local vascular or
mechanical factors, supplemented possibly by delayed hypersensitivity responses in
some patients.
KAPOSI'S sarcoma is primarily cut-
aneous, though it may involve many
tissues in the body (Lothe, 1963). It
was originally described in Hungary by
Kaposi (1>872), but the disease is most
prevalent in equatorial Africa and usually
affects males. The natural history is
variable, and is related both to the gross
morphology and to the histology of the
tumour (Taylor et al., 1971a). Clinically
three main forms can be recognized.
Nodules retain their covering of epi-
dermis, are confined to the skin, grow
slowly and run an indolent course.
Spontaneous complete regression may be
noted in some, whilst an adjacent lesion
may be growing. Such tumours are
usually composed of a mixture of spindle
cells, vascular slits and vascular channels.
Frequently there is fibrosis round the
tumour or lymphocytic infiltration.
Florid(fungating) tumoursgrowrapidly
andulcerate. Theymaypenetrate several
tissue planes to involve underlying bone.
Histologically they are usually mono-
cellular, with a proliferation of large pale
spindle cells, and the vascular component
is less obvious. Mitoses are seen more
frequently in these sections than in those
characterized by a mixed cell pathology
(Taylor et al., 1971a). However, some
of these fungating tumours are frankly
anaplastic and show cellularpleomorphism
and large areas of necrosis. In such
Now at: *The Department ofOrthopaedics, University ofLiverpool, Liverpool L69 3BX; tThe Institute
of Pathology, University of Oslo, Rikshospitalet, Oslo 1, Norway.GROWTH KINETICS OF KAPOSI S SARCOMA
tumours a histological diagnosis may be
impossible unless more typical nodules are
located elsewhere.
Infiltrative tumours and skin plaques
have also been described but are less
common.
The protracted course of nodular
disease led to a search for immunological
responses to the tumour cells and we
have reported delayed hypersensitivity
reactions to autologous tumour cells from
these lesions, demonstrable both in vivo
and in vitro (Taylor and Ziegler, 1974).
However, differing growth rates of
nodular and florid tumours must be an
expression of variation either of the
rate of cell proliferation or of the rate of
cell loss. In the present study we have
calculated these parameters and com-
pared them with the gross morphology.
PATIENTS AND METHODS
Patients admitted to the Uganda Cancer
Institute in 1969 and 1970 with a clinical
diagnosis of Kaposi's sarcoma were poten-
tially available for this study. All were
males, with a duration of symptoms ranging
from 1 month to 8 years. Those excluded
required urgent treatment or withheld in-
formed consent. None had had therapy
within the previous 2 years.
On admission the patients underwent
a full clinical and radiological investigation
and blood count. The cutaneous tumours
were classified as nodular, florid or infiltrative
(Taylor et al., 1971a), and the greatest and
least diameters were measured at right
angles to each other, using a vernier calliper.
Being intracutaneous, the tumours pro-
ject from the skin (Figs. 1 and 2) and were
easily positioned within the blades of the
calliper. The tumours were seen on section
to be intracutaneous spheroids, so no cor-
rectionforskinthickness was made. Tumour
volume was computed, using the 2 diameters
measured, and the mean of these as an
estimate of the third diameter, as ir/6 times
the product of the 3 diameters.
The patients were then reviewed as
out-patients or in the ward until the time
of the second measurement. This was
followed by a biopsy from one edge of the
lesion (Biopsy 1). In 4 patients, biopsies
were taken both from a florid tumour and
from an adjacent nodule. The patients
were than given 10 mg Colcemid (Ciba) i.v.
Four hours later the remainder ofthe tumour
FIG. 1.- The instep of the left foot from Patient No. 5. A is a nodule confined to the dermis, B
also appeared to be intradermal but C was classified as a florid tumour by virtue of attachments
to deep structures.
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FiG.2. The same foot 18 days later. Nodule A is regressing, B has disappeared altogether, but
the flori(d lesion C has increased in size. No treatment had been given in the interval. These
tumours on the foot were not measured for this study of cell kinetics as other more proximal
ttumouirs were more clearly demarcated.
was removed by biopsy excision (Biopsy 2).
All these procedures were approved by the
Makerere Ethical Committee. The biopsy
specimens were fixed in formalin and em-
bedded in wax. Thin (4-jum) sections were
stained with haematoxylin and celestine
blue.
Tumour cell nuclei were counted using
a x 1000 oil immersion lens, and a graticule
square. Consecutive areas were examined
using the microscope vernier, but necrotic
areas were excluded from the count. The
cells adjacent to vascular slits were counted,
but capsular fibrocytes and endothelial cells
lining formed blood vessels were not included.
The metaphases in 5 x 1000 spindle cells
were recorded for each biopsy.
The mitotic count (M) is given as the
number of mitoses in Biopsy 1 per 1000
cells. The rate of cell production (R) is
the slope of the regression line from Biopsy 1
to the observed mitotic count in Biopsy 2
with Colcemid. This method was considered
to be the best way to find the rate of cell
production and to calculate the mitotic
duration (Elgjo, 1966). The actual cliinical
growth rates were calculated from the
formula
Vt = vo .exp r . t
where (Vt) is the designation for tumour
volume at time t, and where the clinical
growth rate (r) will equal
R -L,
where
R = rate of cell production, and
L = rate of cell loss.
The growth rate r was then found by sub-
tracting the natural logarithm of volume 1
(ln V1) from ln V2, and dividing this by
the time interval, t2 -tl. Thus
r In V2 - In Vi)
t2-tl
The actual clinical doubling times (TD)
were then calculated from the formula
TD = ln 2.
r
The potential doubling times (TP) were
then calculated from the similar formula
T _
In 2. T- R
For a description of this method, see Refsum
and Berdal (1967), and Bjerknes (1974).
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The discrepancy between the actual
doubling time (TD) and the potential
doubling time (T.), is the rate of cell loss,
which may be calculated from the formula
L = R-r
From the rate of cell loss we may calculate a
cell loss factor, expressing the rate of cell loss
as a fraction of the rate of cell production:
A = L/R
Values of A > 10 imply that cells are lost
faster than they are created in the tumour,
and the tumour is thus shrinking.
The mitotic duration (D) has been cal-
culated by dividing the mitotic count (M)
without Colcemid by the mitotic rate (R)
D M
R
RESULTS
General
It is difficult to obtain accurate
knowledge of human tumour cell kinetics
because of the nature of the observations.
The material is small, almost all methods
are time consuming and, for ethical and
practical reasons, only a few methods can
be applied to man. The biological varia-
tion is also very wide.
We have chosen to present the results
as actual values measured and calculated,
and in many cases we have calculated
the mean value for nodules and florid
tumours which must be looked upon
in the light of the above reservations.
For a general discussion of the kinetic
characterization of malignant tumours,
see Iversen (1976).
The patients and their tumours
Nine patients were examined (Table
I). Three of the nodules increased in
size, but 3 others showed measurable
regression. All the florid tumours in-
creased in size. The nodular tumour of
Patient No. 9 showed no change in size,
and the cell loss factor is very nearly
equal to 1.0. Patient No. 5 died of his
disease, and No. 3 had amputation of his
leg with florid tumour. All others im-
proved with appropriate chemotherapy
(Vogel et al., 1971). Four patients (Nos.
1, 3, 4 and 5) had both nodular and
TABLE I. Clinical Measurements and Calculated Actual Growth Rates for 13 Turmours
from 9 Patients
Patient
No.
1
2
3
3
4
4
5
5
6
7
8
9
Gross
tumour
morph-
ology*
N
F
N
N
F
N
F
N
F
N
F
F
N
Interval
between
measure-
ments:
t2-t1 (clays)
15
15
165
35
47
32
32
18
18
19
15
180
22
Size at time Size at time
t1
(mm)
13 x 10
17 x 18
30 x 15
4-5 x 8-0
10x7-0
6-5 x 6-5
22-6x 19-3
11 -5x 12-0
15-5 x 22-8
10-Ox 10-0
48 x 49
2 x 2
32 x 33
t2
(mm)
13-5x 12-5
21 x 17
32 x 21
13-5 x 12-5
lOx 16-2
6 - 3 x 6 - 5
25 x 21
9-2 x I1 -0
20-5 x 34-0
9-1 x9 8
51 x 48
36 x 33
32 x 33
Vit
mm3
783
2804
5301
118
312
144
4785
849
3544
524
59728
4
17970
V2t
mm3
1149
3552
8324
1149
1111
137
6322
535
9945
441
63447
21460
17970
* N = Nodular, F = Florid
t V= 6 D,D D where D= D1 + D2 6
2 3 3 ~~~~2
33
Actual
growth
rate
(r)
1-1
0-7
0-1
2-7
1*1
-0-1
0-4
-1-1
2 -4
-0-4
0-2
2 0
0
Actual
doubling
time
TD (h)
651
1056
4861
256
615
-11385
1910
-649
290
-1848
4130
351
00
473J. F. TAYLOR, 0. H. IVERSEN AND R. BJERKNES
TABLE II.-Mitotic Counts and Calculated Potential Doubling Times for 7 Nodular
Tumours
Mitotic count
per 1000 cells*
Patient A--- --__
No. ml M2
Growing
1
2
3
Mean
(s.d.)
Decreasing
4
5*
6
Mean
(s.d.)
Static 9
Overall Mean
(s.d.)
5 -4
13 -2
7 0
8 -5
(4.1)
14-6
2 0
7 0
7 9
(6 4)
13 -0
22 -4
30-8
22-1
(8 9)
20-2
12 -0
10-0
14-1
(5 4)
4-0 6-0
7-6 16-3
(4-7) (8 5)
Mitotic rate
R
per 1000
cells/h
3 -3
5-6
7-7
5 -5
(2 2)
5-1
3-7
2 -5
3-8
(1-3)
Mitotic
duration
D = M/R
(h)
1-7
2 -4
0 9
1-6
(0 7)
2-9
0 5
2-8
2-1
(1 -4)
Cell loss
Potential rate
doubling time L = R- r
Tp ln 2/R per 1000
(h) cells/h
213 3
123-8
90.0
142 -4
(63 7)
137 -3
187-7
277 - 3
200- 8
(70 9)
1-5 2-7 462-1
4-2 2-0 213- 1
(2-1) (1-0) (126-3)
2 -2
5.5
5.0
4-2
(1-8)
5-1
4-8
2 9
4-3
(1-2)
Cell loss
factor
A= L/R
0 7
1 0
0 7
0-8
(0 2)
1.0
1-3
1 -2
1 -2
(0-1)
TABLE III.-Mitotic Counts and Calculated Potential Doubling Times for the 6 Florid
Turnours
Mitotic count
per 1000 cells*
M1 M2
15 2 18 6
21-8 23-4
14-0 31-4
7 0 17-4
11-4 23-0
6-6 17-0
12-7 23-3
(5-7) (6 9)
Potential
doubling time
Tp = ln 2/R
(h)
149-1
118 -5
88-3
129 -5
120-1
163-1
128 -2
(26 -1)
* The interval between biopsies was 4 h, except for Patient No. 5 in whom it was 3 - 25 h.
TABLE IV. A Comparison of Nodular and Florid Tumours Seen Together in Each of 4
Patients
Nodular tumours
Actual Mitotic rate
doubling time R
TD per 1000
Histology (days) cells/h
Mixed 27 -1 3 3
Mixed 10- 7 7 7
Monocellular -474 -4 5- 1
Anaplastic -27 - 0 3 - 7
Histolog
Mixed
Anaplastic
Monocellular
Anaplastic
Florid tumours
Actual Mitotic rate
douibling time R
TD per 1000
yly (days) cells/h
44 0
25-6
79-6
12-1
4 7
5 9
7-9
5.-4
* The interval between biopsies was 4 h, except for patient No. 5 in which it was 3 -25 h.
1-5 1.0
3-8 1-0
(1-6) (0 2)
Patient
No.
1
3
4
5*
7
8
Mean
(s.d.)
Mitotic rate
R
per 1000
cells/h
4.7
5.9
7.9
5-4 5-4
4.3
5-6
(1 -3)
Mitotic
duration
D = M/R
(h)
3 -3
3-7
1 -8
1 3
2 0
1 6
2-3
(1 -0)
Cell loss
rate
L = R- r
per 1000
cells/h
4 0
4-7
7 -5
3 0
5-6
2 -3
4-5
(1-9)
Cell loss
factor
.= L/R
0 9
0 8
1.0
0-6
1.0
0 5
0-8
(1.9)
Patient
No.
1
3
4
5
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florid tumours. The florid tumour from
Patient No. 3 was necrotic, and showed
only a small effect of Colcemid, but the
measurements are included in the results.
The co-existing nodular and floridtumours
were unusual in having similar histo-
pathology in all but one patient (Table
IV). With the exception of these 4
patients, however, nodular tumours had
a mixed cell histological pattern and the
florid tumours were monocellular, with
sheaves of spindle cells predominating.
Delayed hypersensitivity responses were
estimated to a variety of synthetic
antigens, and to autologous tumour ex-
tract, in all but Patients 9, 2 and 6.
Florid lesions were used as a source of
tumour cells in those patients with that
form of the disease. The results showed
negative responses to tumour extract in
all patients, and generally impaired re-
sponses to synthetic antigens in those
with florid lesions (Taylor et al., 1971b).
Actual growth rate
There was considerable spread in the
actual doubling times ofgrowing tumours,
the longest being in Patient No. 2, who
had nodules alone. The growing nodules
had a range of doubling times from
10-65 to 202-55 days (mean 80 i 106)
whilst halving times for regressing no-
dules varied between 27 and 474 days
(mean 193 : 245).
The range of the actual clinical doub-
ling times for the florid tumours was
from 12-09 to 172-10 days, with a mean
of 58 + 61 days. There is no statistically
significant difference between the actual
clinical doubling times of the growing
nodular tumours (80 days) and the florid
tumours (58 days), but if the whole
group of nodular tumours, including the
static and the decreasing tumours, are
considered, our tumour measurements
may be said to confirm earlier reports
(Kyalwasi, 1969; Taylor et al., 1971a),
of a difference in growth rate between
nodular and florid tumours, the former
having the longer doubling time.
Cellular kinetics
Spindle cells formed the greater part
of all tumours, blood vessels and fibrous
strands being rare, but necrotic areas
were seen in florid tumours. The cells
adjacent to vascular slits appeared to
divide more frequently than others. The
appearance after Colcemid confirmed ear-
lier reports (Clarke, 1971), but anaphases
and telophases were not seen.
The mitotic count was very variable,
with a slight tendency to lower values
forthe nodularthanforthe florid tumours.
The differences (7-6 against 12-7 mitoses
per 1000 cells) is not statistically sig-
nificant using Student's t test (0-2 >
P > 0.1). The florid tumour of Patient
No. 1 had a mixed cell pattern but a
high mitotic count. This was reported
as unusual by the pathologist making
the initial diagnosis. There was no dif-
ference between the rates of cell pro-
duction in the two forms of tumour,
which were 4-20 and 5-62 per 1000 cells/h
in nodular andflorid tumoursrespectively.
The calculated mitotic duration varied
widely, from 0 54 h in a decreasing
tumour to 3-73 h in a florid tumour, and
it was therefore not possible to correlate
the mean figures with tumour morph-
ology. The potential doubling times also
varied considerably, from 90 h in a
growing nodular tumour to 462 h in the
single static tumour. The great variation
forbids any comparison of means.
The cell loss factor was similar for
florid tumours and growing nodular tu-
mours, but significantly higher for de-
creasing nodular tumours (0.01 > P >
0 001, Student's t test). The regression
of nodular tumours is due to a combina-
tion of a normal rate of cell production
and a very high rate of cell loss. Thus,
at the time of observation, these tumours
lost each hour 30% more of their spindle
cells than were formed by division. The
slight tendency to a more rapid clinical
growth in the florid tumours than in the
growing nodular tumours may be a
consequence of both a slightly higher
mitotic rate and a slightly lower cell loss
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factor in the increasing nodular tumours
than in the florid tumours. However,
these differences are not statistically
significant.
DISCUSSION
The measurement of the parameters
of the cell population kinetics in clinical
tumours is, as mentioned, always difficult.
Our results are based on relatively few
observations made with methods of mod-
erate exactness. The results should there-
fore be accepted only as provisional, and
certainly not as exact values. This is
especially so for the calculated averages
within each group.
Tumour measurements in patients
with Kaposi's sarcoma show that, when
growing, this tumour behaves like many
other human malignancies. The clinical
doubling time of growing nodular and
florid tumours varied from 11 to 203 days,
1 tumour was static while under observa-
tion, and 3 tumours regressed, with
halving times varying from 27 to 474
days. In fibrosarcomas the clinical doub-
ling time varies from 32 to 275 days
(Breur, 1966).
Comparisons have been made between
Kaposi's sarcomata and lymphomata,
particularly Hodgkin's disease (Lukes and
Butler, 1966), and Burkitt's lymphoma
(McKinney, 1967). The growth rate of
Kaposi's sarcoma is similar to that of
Hodgkin's disease (Charbit, Malaise and
Tubiana, 1971), but much slower than
Burkitt's lymphoma, which has a doubling
time of 3 days (Iversen et al., 1974).
The calculation of cell production
rate is based on arrest by Colcemid of
the dividing cells in metaphase. Tannock
(1967) doubted that colchicine was an
ideal stathmokinetic drug, but Nome
(1975) showed that this objection is not
valid for Colcemid when a correct interval
between injection and measurement is
chosen. There is evidence in the litera-
that stathmokinetic methods may be
used favourably to study tumour kinetics
over a 4-h period (Iversen, 1967; Refsum
and Berdal, 1967; Smith, Thomas and
Riches, 1974). Anaphases and telophases
were not seen in the sections from tumours
exposed to Colcemid, and this leads us
to believe that the block was complete,
and supports previous observations in
Burkitt's lymphoma (Iversen et al., 1974).
The small Colcemid effect in one of the
florid tumours was probably partly due
to impaired vascular supply, areas of
necrosis being seen in the histological
sections. The significance of areas of
necrosis in kinetic calculations can be
assessed using methods such as that
reported by Smith et al. (1974).
The stathmokinetic method has been
used to measure cell production in ex-
perimental tumours (Elgjo, 1966; Nome,
1975). Following an initial biopsy and
injection of Colcemid, further biopsies
were taken at 30-min intervals. A graph
of arrested metaphases (Y axis) plotted
against time (X axis) revealed that the
line of best fit, when projected down-
wards, crossed the Y axis at a point
close to zero. In calculating the mitotic
rate of mouse epidermis Elgjo found
that there was little difference between
the result using the line of best fit, and
that obtained by drawing a line from
the mitotic count 4 h after Colcemid to
the intercept of the X and Y axes. This
finding may be explained by the observa-
tion that the mitotic count without a
stathmokinetic substance, which com-
prises all mitotic phases, is almost always
higher than the initial counts after
Colcemid. Thus after the injection of
a stathmokinetic substance the mitotic
count regularly falls during 30 min and
then rises again. At 1 h the number
of metaphase arrests is similar to the
count without stathmokinesis, and only
increases thereafter.
The mitotic rate of human tumours
would ideally be measured using the
slope of the line of best fit through serial
observations. However, this is impos-
sible because patients cannot be exposed
to a series of biopsies at 30-min intervals.
In view of the work of Elgjo (1966) and
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Nome (1975), we feel that under these
circumstances the most accurate method
of measuring the cell production is to
use the slope of a straight line from the
X and Y intercept through the mean
value ofthe mitotic index at 4 h.
Measurement of the rate of cell pro-
duction gave a mean of about 4-5 cells/
1000 cells/h, with a range of 1U5 to 7-9.
This shows that the cells of Kaposi's
sarcomas multiply more slowly than
the cells of many other human tumours.
Studies reported in the literature (for
review, see Iversen, 1976) show that
there is wide variation in the proliferative
activity of different types of malignant
tumours, of different tumours of the
same histological type, and even of
different areas of histologically similar
fields from the same tumour. When the
cell production rate is used for calculation
of the potential doubling time, the results
for human malignant tumours given in
the literature show variations from 2 to
100 days.
Calculations of the mitotic duration
gave values around 2 h, with a range of
0 54 to 3-73. The mitotic duration in
normal tissues is usually around 1 h.
A prolonged mitotic duration has been
observed in some tumours (Iversen, 1976),
and a long mitotic duration probably
contributes to the high number of mitoses
seen in many tumours.
The cell loss factor in Kaposi's florid
and growing nodular tumours (viz. 0.8)
is similar to values reported from other
human malignancies in the literature
(for a review, see Iversen, 1976).
One of the tumours was not growing,
and 3 were apparently regressing. In
the case of Patient No. 4 the measured
difference in diameter from the first to
second occasion was only 0'2 mm and
may have been due to local pressure by
garments or bedclothes. However, these
patients with regressing tumours were
under observation in a ward between
measurements and, as the epidermal
covering was intact at the second measure-
ment, we believe that the results reflect
real loss of tumour tissue and not the
result of local trauma. These 3 tumours
had cell loss factors higher than 1*0, and
such results have never before been
reported in kinetic studies of human
malignancies. It is also likely that the
regressing tumours had a growth fraction
of considerably less than 1-0. The cell
proliferation rate is calculated as the
rate of cells entering mitosis/1000 cells
among all viable cells, and is thus not
dependent upon knowledge of the growth
fraction in these tumours. The fact
that some tumours grew, while others
regressed, is not due to technical diffi-
culties in measurement, but is an obvious
clinical observation, as shown in the
examples in Figs. 1 and 2.
Regrettably, none of our patients
had both a growing and a regressing
nodule which we were able to measure
(see Figs. 1 and 2). Unusually, in 3
patients with co-existent nodules and
florid tumours, the 2 forms had the same
histological pattern (Table IV). In the
first (Patient No. 1), the nodule was
atypical and exhibited faster growth and
a higher proliferation rate than the
florid lesion. In 2 patients (Nos. 4 and 5)
nodular regression was associated with
a low proliferation rate and high cell
loss
The mean mitotic rate for nodules
(4-2/1000 cells/h) was lower than that
for florid lesions (5.6) and the potential
doubling time was correspondingly in-
creased, being 213 h for nodules and
128 h for the florid lesions. These ob-
servations further characterize the 2
clinical groups. However, there is also
a higher rate of cell loss in the florid
tumours, and it may be that a high
growth fraction is partly responsible for
the rapid increase in size seen in some
of these lesions.
It is possible that the cells of the
regressing nodules carried an antigen not
present in the cells of the florid lesion,
and that immune responses to that
antigen were responsible for the regres-
sion. This appears unlikely, as the 2
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forms of tumour had similar histology.
Moreover, in those patients with fungating
tumours, delayed hypersensitivity re-
sponses were depressed to synthetic anti-
gens and absent to an extract made
from cells of the fungating tumour.
Another explanation appears to be that
some local factor was responsible for the
regression. This might be physical pres-
sure due to inelasticity of skin collagen
in the more superficial tumours. Alter-
natively, it may be that there is in fact
a smaller growth fraction of the cells in
these regressing tumours, and that the
other cells manufacture vasoactive sub-
stances such as those described by Bhana,
Hillier and Karim (1971) which, acting
locally, restrict or impair vascular per-
fusion. Local factors may be supple-
mented by cell-mediated immune mechan-
isms directed against tumour antigens
in those patients where all the nodules
show spontaneous regression.
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